• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Galapagos NV (Amendment)

    2/14/24 5:41:32 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email
    SC 13G/A 1 glpg13ga.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)

    Galapagos NV

    (Name of Issuer)

    Ordinary Shares, no par value

    (Title of Class of Securities)

    36315X1011

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

    1 See Item 2(e).

     

    1.Names of Reporting Persons.

    EcoR1 Capital, LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 6,505,890
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 6,505,890

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,505,890

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.9%

     

    12.Type of Reporting Person (See Instructions) OO, IA

     
     

     

     

    1.Names of Reporting Persons.

    Oleg Nodelman

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 6,505,890
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 6,505,890

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,505,890

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.9%

     

    12.Type of Reporting Person (See Instructions) IN, HC

     

     
     

     

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital Fund Qualified, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power -0-

     

    6. Shared Voting Power 6,135,137
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 6,135,137

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,135,137

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.3%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     
     

     

     

    Item1.
    (a)Name of Issuer

    Galapagos NV

     

    (b)Address of Issuer’s Principal Executive Offices

    Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

     

    Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    357 Tehama Street #3, San Francisco, CA 94103

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Ordinary Shares, no par value (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 36315X101.

    This is the CUSIP for the Issuer’s American Depositary Shares.

     
     

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Mr. Nodelman.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The amounts reported above include (1) Ordinary Shares of the Issuer and (2) American Depositary Shares, each of which represents 1 Ordinary Share of the Issuer.

    The percentages reported in this Schedule 13G are based on 65,897,071 Ordinary Shares outstanding as of June 30, 2023, as reported in the Form 6-K filed by the Issuer on August 4, 2023.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

    EcoR1 is the general partner and investment adviser of investment funds. Mr. Nodelman is the control person of EcoR1.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     
     
     

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: February 14, 2024

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     
    Get the next $GLPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    8/24/2023Buy → Neutral
    Citigroup
    5/5/2023Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Announces Executive Leadership Updates

      Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo  Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today makes two executive leadership announcements. In line with its planned separation

      4/21/25 4:10:00 PM ET
      $GLPG
      $NMRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

      Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos' transformation into a cell therapy company. The company expects to announce Mr. Huston's successor in the coming months.Paul Stoffels1, MD, CEO and Chair of the B

      4/15/25 1:30:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Galapagos NV

      SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

      11/12/24 9:55:16 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Galapagos NV

      SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

      10/8/24 4:35:06 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Galapagos NV

      SC 13D - GALAPAGOS NV (0001421876) (Subject)

      8/23/24 4:01:26 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Financials

    Live finance-specific insights

    See more

    $GLPG
    SEC Filings

    See more

    $GLPG
    Leadership Updates

    Live Leadership Updates

    See more
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

      Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G

      2/12/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

      Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncologyManagement to host conference call today at 14:00 CET / 8:00 am ET MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GL

      1/8/25 1:30:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/29/25 4:44:24 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/23/25 5:19:27 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/21/25 5:30:59 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

      Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company.  The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2024 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the honor to invite its shareholders, holders of subscription rights, Board members, and

      3/27/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

      Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelerate innovation and create near-and long-term value.  "We are pleased to welcome Oleg Nodelman to the Galapagos Board," said Dr. Paul Stoffels, Galapagos' CEO and Chair of the Board of Direc

      10/7/24 1:00:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

      Publication of annual report for financial year 2023Annual Shareholders' Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders' Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders' Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of t

      3/28/24 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Galapagos NV downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

      2/14/25 8:06:36 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos NV downgraded by Kepler

      Kepler downgraded Galapagos NV from Hold to Reduce

      11/20/24 7:41:53 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Galapagos NV with a new price target

      Leerink Partners initiated coverage of Galapagos NV with a rating of Market Perform and set a new price target of $24.00

      9/9/24 7:50:07 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care